enVVeno Medical Corp

enVVeno Medical Corp

NVNO · NASDAQ · Healthcare / Medical Devices

6.17USD-0.41 (-6.16%)

Price History

Full chart

Market Stats

Previous Close6.58
Open6.50
Day Range6.14 – 6.63
52-Week Range7.01 – 35.18
Volume7.52K
Market Cap6.02M
P/E (TTM)0.00
Forward P/E0.00
EPS-24.97
Dividend Yield0.00%
Beta1.07
50-Day Avg10.48
200-Day Avg10.85

About

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Robert A. Berman
  • Employees33
  • Headquarters70 Doppler, Irvine, CA, United States, 92618, USA
  • Websitehttps://www.envveno.com

Leadership

  • Mr. Robert A. BermanCEO & Director · b. 1963
  • Ms. Jennifer Bright CPAChief Financial Officer · b. 1971
  • Dr. Hamed Alavi Ph.D.Senior VP & Chief Technology Officer · b. 1984
  • Dr. Marc H. Glickman M.D.Senior VP & Chief Medical Officer · b. 1949
  • Ms. Sandy PriettoVice President of Marketing
  • Mr. Avi SharmaSenior Vice President of Clinical, Regulatory & Quality

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue236.50K-785.91K422.11K186.55K31.24K000000
Growth (%)----46.29%-55.80%-83.25%-100.00%-----
Cost of Revenue266.44K125.42K961.47K558.87K0-383.97K452.91K525.00K546.00K528.00K489.00K
Gross Profit-29.94K-125.42K-175.56K-136.76K186.55K31.24K-383.97K-452.91K-525.00K-546.00K-528.00K-489.00K
Gross Margin-12.66%--22.34%-32.40%100.00%100.00%------
Operating Expense922.72K1.16M4.48M5.97M8.04M7.71M8.75M16.44M24.41M24.69M23.30M20.41M
Operating Income-952.66K-1.29M-4.66M-6.10M-7.85M-7.68M-9.14M-16.89M-24.93M-25.24M-23.83M-20.90M
Operating Margin-402.82%--592.84%-1445.89%-4210.51%-24566.50%------
EBITDA-818.53K-1.16M-5.38M-5.73M-6.05M-7.23M-8.75M-16.07M-24.14M-22.97M-21.29M-18.98M
EBITDA Margin-346.10%--684.45%-1358.08%-3242.20%-23134.14%------
Net Income-1.40M-1.60M-5.89M-7.79M-13.04M-7.63M-9.14M-16.53M-24.67M-23.52M-21.82M-19.47M
Net Income Margin-591.12%--749.01%-1845.83%-6991.46%-24406.74%------
R&D---649.74K1.24M2.21M4.25M5.73M9.91M13.58M12.25M9.98M
R&D as % of Total Revenue---153.93%664.02%7061.17%------
Interest Expense65.49K88.52K57.89K1.92M6.86M9333.74K18.71K263.00K---
Interest Expense % of Total Revenue27.69%-7.37%454.77%3677.74%2.99%------

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.60M2.87M1.78M2.21M3.56M3.43M10.54M57.70M41.66M48.63M44.95M29.56M
Total Liabilities3.61M4.66M2.07M8.17M1.52M2.44M3.44M3.29M2.93M2.44M2.79M2.43M
Total Equity-2.01M-1.78M-4.22M-11.13M2.04M989.94K7.10M54.40M38.73M46.20M42.16M27.13M
Cash58.03K1.59M56.51K77.69K2.74M1.31M9.33M54.73M4.55M3.62M1.75M3.06M
Total Debt1.07M1.83M632.77K2.62M-856.63K880.65K2.01M1.72M1.40M1.06M700.00K
Net Debt1.01M245.70K576.26K2.54M-2.74M-450.60K-8.45M-52.72M-2.84M-2.22M-690.00K-2.37M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow121.74-2.02M-3.42M-4.20M-6.36M-5.90M-7.68M-11.85M-15.62M-18.86M-16.84M-15.57M
Investing Cash Flow-30.88-77.62K-372.77K165.31K-12.42K-363.89K-180.29K-368.00K-34.55M-7.87M1.33M15.86M
Financing Cash Flow-603.62M2.26M4.06M9.03M5.64M15.07M57.61M-4.11K25.79M13.64M1.02M
Capital Expenditure30.882.62K373.62K10.94K12.42K363.89K180.29K368.00K115.00K33.00K37.00K5.00K
Free Cash Flow90.86-2.02M-3.79M-4.21M-6.37M-6.26M-7.86M-12.22M-15.73M-18.89M-16.88M-15.57M
FCF to OCF74.63%100.13%110.93%100.26%100.20%106.17%102.35%103.11%100.74%100.17%100.22%100.03%

Earnings

Report DateSep 7, 2017Dec 14, 2017Mar 7, 2018May 22, 2018Aug 29, 2018Nov 28, 2018Feb 27, 2019Jun 13, 2019Aug 5, 2019Oct 31, 2019Mar 18, 2020Jun 8, 2020Aug 14, 2020Nov 6, 2020Mar 31, 2021May 12, 2021Aug 11, 2021Nov 12, 2021Mar 28, 2022Apr 29, 2022Aug 3, 2022Oct 27, 2022Mar 2, 2023Apr 28, 2023Jul 31, 2023Oct 26, 2023Feb 29, 2024May 8, 2024Jul 31, 2024Oct 31, 2024Feb 28, 2025May 6, 2025Jul 31, 2025Nov 28, 2025Feb 26, 2026May 6, 2026Jul 30, 2026Oct 30, 2026
EPS Estimate0.000.000.000.00--0.68-0.28-0.27-0.11-122.50-113.75---43.75-34.30-0.34-11.90-11.90-11.55-0.29-11.55-18.20-0.57-16.80-17.15-16.80-0.46-14.00-12.60-11.55-12.25-0.34-9.80-0.30-0.28-8.40-4.69-
EPS Actual-0.12-0.210.02-0.11-1.06-0.13-0.28-0.13-0.13-87.50-113.75-0.06-0.08-70.00-257.25-0.48-9.80-9.10-32.90-0.47-22.05-18.90-0.55-19.95-20.30-15.75-0.36-10.85-10.85-12.25-10.50-0.22-11.55-0.23-5.91-5.89-5.37-
Surprise-----80.88%0.00%51.85%-18.18%28.57%0.00%---60.00%-650.00%-41.18%17.65%23.53%-184.85%-62.07%-90.91%-3.85%3.51%-18.75%-18.37%6.25%21.74%22.50%13.89%-6.06%14.29%35.29%-17.86%23.33%-2010.43%29.88%-14.50%-
Timing-------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hours--After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap6.02M
Enterprise Value-14.96M
Trailing P/E0.00
Forward P/E0.00
Price / Sales216.91
Price / Book0.29
EPS-24.97
Book Value30.71
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-17.26M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-58.53%
Return on Assets-36.68%
Shares Outstanding694.83K
Shares Float590.41K
Beta1.07
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 30.00
  • Strong Buy
    1

Ownership Breakdown

Institutions
15.96%
Insiders
8.23%
Retail / Other
75.81%

Top Institutional Holders

  • Kingdon Capital Management LLC
    36.17K5.21%
  • CM Management, LLC
    35.71K5.14%
  • Geode Capital Management, LLC
    10.46K1.50%
  • Vanguard Capital Management, LLC
    6.29K0.90%
  • JPMorgan Chase & Co
    5.21K0.75%
  • Vanguard Fiduciary Trust Co
    2.18K0.31%
  • BlackRock Inc
    1.84K0.26%
  • Westside Investment Management, Inc.
    1.52K0.22%
  • Tower Research Capital LLC
    5420.08%
  • Mirae Asset Global Investments (Korea) Co Ltd
    5390.08%
  • UBS Group AG
    2430.04%
  • Wells Fargo & Co
    1140.02%
  • Allied Private Wealth LLC
    880.01%
  • Vanguard Global Advisers, LLC
    770.01%
  • Morgan Stanley - Brokerage Accounts
    760.01%

Top Fund Holders

  • Fidelity Extended Market Index
    3.31K0.48%
  • Fidelity Total Market Index
    8410.12%
  • Fidelity Series Total Market Index
    8050.12%
  • Fidelity Nasdaq Composite Index
    1760.03%
  • Vanguard U.S. Eq Idx £ Acc
    770.01%

Stock Splits

  • Jan 20, 20261:35
  • Nov 30, 20201:25